SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion: 52-Week Results from a Phase 3 Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Linni, Li Zhiqing, Ren Xinjun, Tan Liangzhang, Zhao Shuo, Lu Yingyi, Hao Jilong, Wu Miaoqin, Xu Xinyan, Shi Huijun, Ren Qian, You Zhipeng, Song Yanping, Zhang Wenfang, Lei Chunling, Zhang Ximei, Wang Xian, Tan Wei, Yuan Songtao, Tao Liming, Chen Changzheng, Song Zongming, Zhuang Wenjuan, Zhang Hong, Han Quanhong, Jin Yu, Peng Jianjun, Zhang Qing, Gao Jianlu, Pan Xuemei, Shen Ye, Li Mingxin, Wang Jianfeng, An Liangbao, Liu Xiaoling, Li Jun, Chen Lixun, Wang Hong, Zhang Jinglin, Zhou Zixia, Zhong Jingxiang, Wang Yanling, Zhang Tonghe, Xiong Wei, Cui Ling, Peng Xiaoyan, Yang Mochi, Zhang Ming, Li Zhuo, Wang Hailin, Lou Jing, Liu Yanli, Dai Hong, Li Xiaorong
Аннотация
DESIGN: A multicenter, randomized, double-masked, active-controlled phase 3 clinical study.
PARTICIPANTS: A total of 351 patients with macular edema secondary to BRVO were enrolled.
METHODS: Evaluable patients (N=351) were randomized to receive intravitreal SSGJ-601(1.25mg per eye, Q4W) or intravitreal ranibizumab (0.5mg per eye, Q4W) from day 1 through week 20 (6 injections in total), and treatment transitioned to a pro re nata (PRN) schedule based on investigator-assessed retreatment criteria from week 24 to week 48. All patients completed their end-of-study visit at week 52.
MAIN OUTCOME MEASURES: The primary efficacy endpoint was the Least Squares (LS) mean difference in change in best-corrected visual acuity (BCVA), measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score, from baseline to week 24. Secondary efficacy endpoints, safety, pharmacokinetics, immunogenicity and change in VEGF concentration of SSGJ-601 were also analyzed.
RESULTS: Demographic and baseline characteristics and exposure to treatment were similar between groups. In the study eye, SSGJ-601 was non-inferior to ranibizumab in improving the LS mean in BCVA letter count from baseline to week 24 (17.6 (0.66) vs. 18.2 (0.65) letters, -0.6 with 95%CI: (-2.4,1.3), P for non-inferior<0.0001), thus, the primary clinical efficacy end point was met. At each time point, the proportions of patients achieving BCVA gains of ≥5, ≥10, and ≥15 letters in the SSGJ-601 group were non-inferior to those in the ranibizumab group. Drug-related TEAEs (11.4% vs. 12.5%) and SAEs (6.9% vs. 9.1%) were comparable in the two treatment groups. A low incidence of binding antidrug antibodies was observed in SSGJ-611 group.
CONCLUSIONS: This study supports the conclusion of no clinical meaningful differences in efficacy, safety, and immunogenicity between SSGJ-601 and ranibizumab in patients with macular edema secondary to BRVO. Additionally, treatment transitioned to a pro re nata (PRN) schedule based on investigator-assessed retreatment criteria resulted in sustained benefits in visual and anatomical outcomes.